|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
A 47-year-old female with ALK-rearranged lung adenocarcinoma developed leptomeningeal metastasis (LM) after progression on first-line crizotinib.
|
31766077 |
2020 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Moreover, the concordance of ALK status was observed in these pairs.<b>Conclusions</b>: Our data suggested that hotspot mutations and ALK status in the primary-metastasis pairs had a high concordance in lung adenocarcinoma.
|
31651223 |
2020 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this study, we aim to validate diagnostic performance of multiplex ALK/ROS1 fluorescence in situ hybridisation (FISH) approach in lung adenocarcinoma cytological series compared with classic single break apart probes.
|
31562206 |
2020 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas.
|
31215177 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutations in 59 cancer-associated genes and fusions of ALK and ROS1 were analyzed to understand the molecular features of young patients with lung adenocarcinoma.
|
31387567 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study elucidated the prevalence and prognostic significance of mutations in the epidermal growth factor receptor gene (<i>EGFR</i>) and rearrangements in the anaplastic lymphoma kinase gene (<i>ALK</i>) in patients with surgically resected primary LAC.
|
30662526 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Molecular Epidemiology of ALK Rearrangements in Advanced Lung Adenocarcinoma in Latin America.
|
30476928 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Approximately 3%-5% of lung adenocarcinoma is driven by anaplastic lymphoma kinase (ALK) fusion oncogene, whose activity can be suppressed by multiple ALK inhibitors.
|
31613427 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma.
|
30658713 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, a TNIP2-ALK fusion has not been reported in lung adenocarcinoma.
|
31521978 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
ALK is a prognostic and predictive tumor marker in non-small cell lung carcinoma (NSCLC), and is more often found in lung adenocarcinomas.
|
31699471 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase (ALK) rearrangement is reported in 3% to 8% of patients with lung adenocarcinoma and can be detected by fluorescent in situ hybridization (FISH) or indirectly by immunohistochemistry.
|
30909092 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
At the molecular test, EGFR overexpression and ALK mutation resulted positive for 12/23 patients with lung adenocarcinoma.
|
31596139 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
At the same time, patient was diagnosed with lung adenocarcinoma in the left lower lobe with positive anaplastic lymphoma kinase mutation and with right lower lobe metastasis.
|
31609765 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
This report describes the clinical course of a female former light smoker with metastatic lung adenocarcinoma whose tumor underwent histologic transformation from a well-differentiated lung adenocarcinoma to a well-differentiated lung squamous cell carcinoma in the same location at the left mainstem bronchus while maintaining the ALK fusion oncogene without any resistance mutations.
|
30959466 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of our work was to describe the rate of EGFR, KRAS, BRAF, and HER2 mutations, and ALK rearrangement and pathologic characteristics in patients with lung adenocarcinoma over 75, compared with patients below 75 years old.
|
30095461 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study was aimed at investigating the prognostic significance of Baculoviral IAP repeat containing 5 (BIRC5) in lung adenocarcinoma (LAD) lacking EGFR, KRAS, and ALK mutations (triple-negative (TN) adenocarcinomas).
|
31093306 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Transfer of Extracellular Vesicle-Associated-RNAs Induces Drug Resistance in ALK-Translocated Lung Adenocarcinoma.
|
30658414 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The KRAS-positive group included higher proportions of cases with an inflammatory background (100%), predominantly papillary architecture (75%), and papillary-type ADC pattern (75%) compared with the EGFR-positive group and the other group, which included ALK and ROS1 gene rearrangements.
|
30741488 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
This study aimed to identify the associations of ALK rearrangement with clinicopathologic features and prognosis in patients with surgically resected stage I-IIIA lung adenocarcinoma.
|
31737311 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
He was diagnosed with anaplastic lymphoma kinase-rearranged lung adenocarcinoma combined with multiple distant metastases.
|
31123682 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate the intertumoral heterogeneity of pathologic and genetic characteristics of multifocal LUAC with EGFR/ALK co-alterations.
|
31138506 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Thus, TP53 mutations and V3 are independently associated with enhanced metastatic spread, shorter TKI responses and inferior overall survival in ALK<sup>+</sup> lung adenocarcinoma.
|
30255938 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma.
|
31455365 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
RESULTS NSE level (P=0.007 for OS) was identified as an independent prognostic factor among patients with resected ALK-positive adenocarcinoma of the lung.
|
30673691 |
2019 |